Medical Advocates
Cytomegalovirus Infection/Disease
  Transplant-Related CMV

General Reports
Prophylaxis
Heart
Lung
 Liver
Kidney
Pancreas
Stem Cell
Umbilical Cord

 
CMV Main Page   Main New/Newsworthy  Home Page 
Last Update:  January 02, 2011
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General/Miscellaneous Reports
       

          Journal Papers, Abstracts, and Commentaries   

 
Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus
Disease in Solid Organ Transplant Recipients.
Eid AJ, Arthurs SK, Deziel PJ, et al
Am J Transplant. 2009 Nov 4
Abstract

Relapsing cytomegalovirus infection in solid organ transplant recipients.
Shanahan A, Malani PN, Kaul DR.
Transpl Infect Dis. 2009 Sep 7.
Abstract

Survey of current practice for prevention of transfusion-transmitted cytomegalovirus
in the United States: leucoreduction vs. cytomegalovirus-seronegative.
Smith D, Lu Q, Yuan S, Goldfinger D, et al
 Vox Sang. 2009 Aug 20.
 Abstract

A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in
(D+/R-) solid organ transplant recipients.
Juan RS, Yebra M, Lumbreras C, et al 
Clin Transplant. 2009 Aug 17
Abstract

Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant
in patients at high risk for cytomegalovirus infection.
Benmarzouk-Hidalgo OJ, Cordero E, et al  
Antivir Ther. 2009;14(5):641-7.
Abstract

 

Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir
or oral valganciclovir.
Boivin G, Goyette N, Rollag H, et al 
Antivir Ther. 2009;14(5):697-704
 Abstract

CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ, Clatworthy MR, Birch R, et al  
 Transplantation. 2009 Jul 15;88(1):77-82.
Abstract

How we treat CMV in hematopoietic cell transplant recipients.
Boeckh M, Ljungman P.  
Blood. 2009 Mar 18.
Abstract
 
Late onset CMV disease in solid organ transplant recipients.
Husain S, Pietrangeli CE, Zeevi A. 
Transpl Immunol. 2009 Jan 19.
Abstract
 
Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset
CMV disease several years after transplantation.
Cummins NW, Deziel PJ, Abraham RS, Razonable RR. 
Transpl Infect Dis. 2009 Feb;11(1):20-7
Abstract
 
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease
in solid-organ transplant recipients.
Torres-Madriz G, Boucher HW.  
Clin Infect Dis. 2008 Sep 1;47(5):702-11.
Abstract
 
FULL-TEXT ARTICLE
Cytomegalovirus infection after liver transplantation: Current concepts and challenges.
Razonable RR.
World J Gastroenterol. 2008 Aug 21;14(31):4849-60.
Paper
 
FULL TEXT ARTICLE
Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
Egli A, Binet I, Binggeli S, et al  
J Transl Med. 2008 Jun 9;6:29.
Paper
 
Host and Donor Immune Responses Contribute to Antiviral Effects of Amotosalen-Treated Donor Lymphocytes
following Early Posttransplant Cytomegalovirus Infection.
Hossain MS, Roback JD, Wang F, Waller EK.
J Immunol. 2008 May 15;180(10):6892-902.
Abstract
 
Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and
indirect effects and prevention strategies.
Varga M, Remport A, Czebe K, et al
Orv Hetil. 2008 Mar 23;149(12):551-8.
Abstract
 
Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate
with risk factors and outcomes?
Levitsky J, Freifeld AG, Puumala S, et al
Clin Transplant. 2008 Mar-Apr;22(2):222-8.
Abstract
 
Cytomegalovirus infection and new-onset post-transplant diabetes mellitus.
Leung Ki EL, Venetz JP, Meylan P, et al"
Clin Transplant. 2008 Mar-Apr;22(2):245-9.
 Abstract
 
FULL-TEXT ARTICLE
Impairment of cytomegalovirus-specific cellular immune response as a risk factor for
cytomegalovirus disease in transplant recipients.
Motta VN, Martins SL.  
Braz J Med Biol Res. 2008 Jan;41(1):5-11.
Paper
 
Current management strategies for the treatment and prevention of cytomegalovirus infection
in solid organ transplant recipients.
Abu-Nader R, Patel R.  
BioDrugs. 2000 Mar;13(3):159-75.
 Abstract
 
A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation
cytomegalovirus.
Pescovitz MD.  Kidney Int. 2007 Oct;72(8):912-3.
 Abstract
 
Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled
study.
Moreno de la Higuera Díaz MA, Calvo Romero N, Sánchez-Fructuoso A, et al
Transplant Proc. 2007 Sep;39(7):2231-2
 Abstract
 
Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K, Brennan DC  
Expert Rev Anti Infect Ther. 2007 Apr;5(2):295-304.
Abstract
 
Etiology and impact of cytomegalovirus disease on solid organ transplant recipients.
McDevitt LM. 
Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl 5):S3-9.
Abstract
 
Cytomegalovirus Viremia, Mortality, and End-Organ Disease Among Patients With
AIDS Receiving Potent Antiretroviral Therapies.
Wohl DA, Zeng D, Stewart P, Glomb N, et al
J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):538-544.
 Abstract
Prophylaxis
       

          Journal Papers, Abstracts, and Commentaries   

 
Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant
recipients.
Oppenheimer F, Gonzalez-Molina M, Rubio M.
Clin Transplant. 2007 Jul-Aug;21(4):441-8.
 Abstract
 
WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ
transplantation.
Couchoud-Heyer C.
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001320.
Abstract
 
Prevention of cytomegalovirus disease in solid organ transplant patients:
Prophylactic versus preemptive therapy.
Baillie GM.  
Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl 5):S10-6.
Abstract
 
Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K, Brennan DC  
Expert Rev Anti Infect Ther. 2007 Apr;5(2):295-304.
Abstract

Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ
transplant recipients.
Cochrane AB. 
Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl
Abstract

Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive
therapy.
Singh N.   
Rev Med Virol. 2006 Sep-Oct;16(5):281-7.
Abstract

Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus
prophylaxis.
Humar A.
Transplantation. 2006 Jul 27;82(2 Suppl):S9-S14.
 Abstract
 
Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
Pescovitz MD.
Transplantation. 2006 Jul 27;82(2 Suppl):S4-8
 Abstract
Heart
       

          Journal Papers, Abstracts, and Commentaries   

 
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil
in de novo cardiac transplant recipients: a randomized, multicenter study.
Viganò M, Dengler T, Mattei MF, et al 
Transpl Infect Dis. 2009 Sep
Abstract

High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after
completion of 3 months of  valganciclovir prophylaxis.
Gupta S, Mitchell JD, Markham DW, et al
J Heart Lung Transplant. 2008 May;27(5):536-9.
Abstract
 
The Influence of Cytomegalovirus Infection, Confirmed by pp65 Antigen Presence, on the
Development of Cardiac Allograft Vasculopathy.
Zakliczyński M, Krynicka-Mazurek A, et al 
Transplant Proc. 2007 Nov;39(9):2866-9.
 Abstract
 
Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac
transplant recipients.
Kijpittayarit-Arthurs S, Eid AJ, et al  
J Heart Lung Transplant. 2007 Oct;26(10):1019-24.
 Abstract
 
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart
transplant recipients.
Li F, Kenyon KW, Kirby KA, Fishbein DP  
Clin Infect Dis. 2007 Aug 15;45(4):439-47.
 Abstract
 
Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection
in a heart transplant recipient.
García-Martínez J, Folgueira L, et al
Transpl Infect Dis. 2007 Jul 1;
 Abstract
 
Frequent occult infection with cytomegalovirus despite antiviral prophylaxis in cardiac
transplant recipients.
Potena L, Holweg CT, Vana ML, et al 
J Clin Microbiol. 2007 Apr 4;
 Abstract
 
Cytomegalovirus infections in cardiac transplant patients: an experience at a clinical
hospital,university of chile.
Sepulveda L, Llancaqueo M, Zamorano J, et al
Transplant Proc. 2007 Apr;39(3):622-4.
 Abstract

Cytomegalovirus infection in heart transplant recipients is associated with impaired
endothelial function.
Petrakopoulou P, Kubrich M, Pehlivanli S,  et al
Circulation. 2004 Sep 14;110(11 Suppl 1):II207-12.
 Abstract
Lung
       

          Journal Papers, Abstracts, and Commentaries   

 
CMV infection is associated with the depletion but lack of activation of peripheral blood natural killer
 cells in a lung transplant cohort.
Fildes JE, Walker AH, Williams SG, et al  
Transpl Immunol. 2008 Jun 17.
Abstract
 
A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant
recipients: treatment and outcome.
Reddy AJ, Zaas AK, Hanson KE, Palmer SM.  
J Heart Lung Transplant. 2007 Dec;26(12):1286-92.
 Abstract
 
CD8(+) T-cell maturation following lung transplantation: The differential impact of CMV and
acute rejection.
Westall GP, Brooks AG, Kotsimbos T. 
Transpl Immunol. 2007 Nov;18(2):186-92.
 Abstract
 
Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic
treatment.
Aoe M, Tao H, Yamane M, Toyooka S, et al
Kyobu Geka. 2007 Oct;60(11):988-92.
 Abstract

Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-
seropositive lung transplant recipients.
Kruger RM, Paranjothi S, Storch GA
J Heart Lung Transplant. 2003 Jul;22(7):754-63.
Abstract
Liver
     

          Journal Papers, Abstracts, and Commentaries   

 
CMV infection, diagnosis and antiviral strategies after liver transplantation.
Lautenschlager I.
Transpl Int. 2009 Jul 10.
 Abstract

High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients.
Halme L, Lempinen M, Arola J,
APMIS. 2008 Feb;116(2):99-106.
 Abstract
 
Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and
review of the literature
Egli A, Bergamin O, Müllhaupt B, Seebach JD, et al
Transpl Infect Dis. 2007 Dec 17
Abstract
 
A Survey of CMV Prevention Strategies After Liver Transplantation.
Levitsky J, Singh N, Wagener MM, et al   
Am J Transplant. 2007 Oct 31;
 Abstract
 
Pre-transplant risk factors predicting post-transplant cytomegalovirus infection in liver
transplant recipients.
Saito T, Egawa H, Kudo T, et al
Transpl Int. 2007 Feb 19;
 Abstract
 
FULL TEXT ARTICLE
Immunomodulatory therapy of cytomegalovirus pneumonia after liver transplantation.
Wang GS, Chen GH, Lu MQ 
Chin Med J (Engl). 2006 Sep 5;119(17):1430-4.
Abstract
 
Cytomegalovirus infection after orthotopic liver transplantation is restricted by a pre-
existing antiviral immune response of the recipient.
Bissinger AL, Oettle H, Jahn G, et al
J Med Virol. 2004 May;73(1):45-53.
Abstract
 
Late cytomegalovirus disease following liver transplantation.
Shibolet O, Ilan Y, Kalish Y, et al
Transpl Int. 2003 Dec; 16(12): 861-5.
Abstract
 

Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after
ganciclovir treatment.
Loginov R, Hockerstedt K, Lautenschlager I. 
Arch Virol. 2003 Jun;148(7):1269-74.
Abstract
Kidney
       
          Journal Papers, Abstracts, and Commentaries   
 
 
Cytomegalovirus infection following renal transplantation in patients administered low-dose
rituximab induction therapy.
Nishida H, Ishida H, Tanaka T,et al  
Transpl Int. 2009 Jul 10
 Abstract

Dose CMV infection increase the incidence of infective endocarditis following kidney transplantation?
Einollahi B, Lessan-Pezeshki M, Pourfarziani V,  et al  
Ann Transplant. 2009;14(1):32-7.
 Abstract
 
Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney
 transplantation.
Hadaya K, de Rham C, Bandelier C, .et al 
Am J Transplant. 2008 Dec;8(12):2674-83.
 Abstract
 
Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using
oral valganciclovir.
Guirado L, Rabella N, Díaz JM, et al  
Nefrologia. 2008;28(3):293-300.
 Abstract
 
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients.
Sadeghi M, Daniel V, Naujokat C,  et al 
Transplantation. 2008 Jul 27;86(2):275-85.
 Abstract
 
Cytomegalovirus infection in renal transplant recipients.
Basić-Jukić N, Racki S, Kes P, Mustapić Z. 
Acta Med Croatica. 2008;62 Suppl 1:69-75.
 Abstract
 
Cytomegalovirus disease in renal transplant recipients: a single-center experience.
Cavdar C, Celtik A, Saglam F, et al 
Ren Fail. 2008;30(5):503-6.
 Abstract
 
Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
Kamar N, Mengelle C, Esposito L, et al
J Med Virol. 2008 Jun;80(6):1012-7.
 Abstract

 
FULL-TEXT ARTICLE
Occurrence of Cytomegalovirus Infection and Factors Causing Reactivation of the
Infection among Renal Transplant Recipients: A Single Center Study.
Khameneh ZR. 
Saudi J Kidney Dis Transpl. 2008 Jan-Feb;19(1):41-5.
 Paper
 
Is combined pretransplantation seropositivity of kidney transplant recipients for
cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection?
Essa S, Pacsa A, Said T, et al 
Med Princ Pract. 2008;17(1):66-70
 Abstract
 
Donor and recipient CMV serostatus and antigenemia after renal transplantation:
An analysis of 486 patients.
Hughes D, Hafferty J, Fulton L, et al  
J Clin Virol. 2007 Nov 19;
Abstract
 
The use of consensus guidelines for management of cytomegalovirus infection in renal
transplantation.
Dmitrienko S, Yu A, Balshaw R, et al  
Kidney Int. 2007 Aug 15
 Abstract

Acute esophageal necrosis (black esophagus) in the renal transplant recipient:
manifestation of primary cytomegalovirus infection.
Trappe R, Pohl H, Forberger A, et al 
Transpl Infect Dis. 2007 Mar;9(1):42-5.
 Abstract

Cytomegalovirus infection in kidney transplant recipients: evolution of approach through
three eras.
Boucher A, Lord H, Collette S, et al 
Transplant Proc. 2006 Dec;38(10):3506-8
Abstract
 
The natural course of cytomegalovirus infection and disease in renal transplant recipients.
Hartmann A, Sagedal S, Hjelmesaeth J.
Transplantation. 2006 Jul 27;82(2 Suppl):S15-7.
Abstract
 
Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous
pancreas-kidney transplant recipients.
Huurman VA, Kalpoe JS, van de Linde P, et al 
Diabetes Care. 2006 Apr;29(4):842-7.
Abstract
 
Variation of CD4(+) and CD8(+) T Lymphocytes as Predictor of Outcome in Renal
Allograft Recipients Who Developed Acute Respiratory Distress Syndrome Caused
by Cytomegalovirus Pneumonia.
Sun Q, Li L, Ji S, Chen J, et al   
Transplant Proc. 2005 Jun;37(5):2118-2121.
 Abstract
 
The impact of early cytomegalovirus infection and disease in renal transplant recipients.
Sagedal S, Hartmann A, Rollag H.
Clin Microbiol Infect. 2005 Jul;11(7):518-30.
 Abstract
Pancreas
       

          Journal Papers, Abstracts, and Commentaries   

 
Preemptive therapy is not adequate for prevention of cytomegalovirus disease
in pancreas-kidney transplant recipients.
López-Medrano F, Rueda B, Lizasoain M, et al
Transpl Infect Dis. 2009 Jun 29
 Abstract

Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney
transplant recipients without ganciclovir prophylaxis.
Rayes N, Seehofer D, Kahl A, et al 
Transpl Int. 2007 Aug 2
 Abstract

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous
pancreas-kidney transplant recipients.
Huurman VA, Kalpoe JS, van de Linde P, et al 
Diabetes Care. 2006 Apr;29(4):842-7.
Abstract
Stem Cell
     

          Journal Papers, Abstracts, and Commentaries   

 
A randomized trial of preemptive therapy for prevention of cytomegalovirus disease
after allogeneic hematopoietic stem cell transplantation.
Kim ST, Lee MH, Kim SY,  et al
Int J Hematol. 2010 May 8
 Abstract

Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem
cell transplantation- single-centre experience.
Piñana JL, Martino R, Barba P, et al
Bone Marrow Transplant. 2009 Aug 10
 Abstract

Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT.
Schmidt-Hieber M, Schwarck S, et al
Bone Marrow Transplant. 2009 Jan 19.
 Abstract
 
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem
cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations
in the UL97 and UL54 genes.
Oshima K, Kanda Y, Kako S, et al  
J Med Virol. 2008 Oct;80(10):1769-75.
 Abstract
 
FULL-TEXT ARTICLE
Colonoscopy in the diagnosis of intestinal graft versus host disease and cytomegalovirus enteritis following
allogeneic haematopoietic stem cell transplantation.
He JD, Liu YL, Wang Z, et al 
Chin Med J (Engl). 2008 Jul 20;121(14):1285-9
 Paper
 
Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation with Alemtuzumab.
Song WK, Min YH, Kim YR, Lee SC. 
Ophthalmology. 2008 Jun 16.
 Abstract
 
Monitoring cytomegalovirus IE-1 and pp65-specific CD4(+) and CD8(+) T-cell responses after allogeneic
stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW, Brooimans RA, van der Holt B,et al  
Cytometry B Clin Cytom. 2008 May 2.
 Abstract
 
HLA-DRB1*09 Is Associated with Increased Incidence of Cytomegalovirus Infection and
Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Du J, Liu J, Gu J, Zhu P.
Biol Blood Marrow Transplant. 2007 Dec;13(12):1417-1421.
 Abstract
 
Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay
in patients undergoing hematopoietic stem cell transplantation.
Morita-Hoshi Y, Heike Y, Kawakami M, et al 
Bone Marrow Transplant. 2007 Nov 19;
Abstract
 
Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell
transplantation using virus-specific T cells.
Mackinnon S, Thomson K, Verfuerth S, et al
Blood Cells Mol Dis. 2007 Sep 13;
 Abstract
 
FULL-TEXT PDF ARTICLE
Factors influencing cytomegalovirus seropositivity in stem cell transplant patients
and donors.
Ljungman P, Brandan R
Haematologica. 2007 Aug;92(8):1139-42.
Paper
 
Survellance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic
hematopoietic stem cell transplantation.
Jia JS, Liu DP, Huang XJ, et al;
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Aug;14(4):749-54
 Abstract
 
The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell
Transplantation Compared with Conventional Bone Marrow Transplantation.
Oh SJ, Lee KH, Lee JH ,et al  
J Korean Med Sci. 2004 Apr;19(2):172-6
 Abstract
 
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell
transplantation: impact of host factors, drug therapy, and subclinical reactivation.
Hakki M, Riddell SR, Storek J, et al  
Blood. 2003 Jul 3
Abstract
Umbilical Cord
       

          Journal Papers, Abstracts, and Commentaries   

 
Impact of Cytomegalovirus (CMV) Reactivation After Umbilical Cord Blood Transplantation.
Beck JC, Wagner JE, Defor TE, et al
 Biol Blood Marrow Transplant. 2009 Sep 25.
 Abstract

Cytomegalovirus Infections following Umbilical Cord Blood Transplantation Using Reduced
Intensity Conditioning Regimens for Adult Patients.
Matsumura T, Narimatsu H, Kami M, et al
Biol Blood Marrow Transplant. 2007 May;13(5):577-83
 Abstract
 

CMV Main Page   Main New/Newsworthy  Home Page 

Transplant Related CMV Infection